HESTERBIOPharmaceuticals
Hester Biosciences Ltd — Cash Flow Statement
₹1259.10
-4.49%
Hester Biosciences Ltd Cash Flow Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Free Cash Flow | 43.92 Cr | 23.79 Cr | -54.17 Cr | -87.00 Cr | — |
| Repayment Of Debt | -33.12 Cr | -50.47 Cr | -17.14 Cr | -18.04 Cr | — |
| Issuance Of Debt | 0.00 | 20.47 Cr | 32.04 Cr | 103.35 Cr | — |
| Capital Expenditure | -20.59 Cr | -24.40 Cr | -77.76 Cr | -95.71 Cr | — |
| End Cash Position | 5.59 Cr | 12.31 Cr | 13.16 Cr | 24.75 Cr | — |
| Beginning Cash Position | 12.31 Cr | 12.67 Cr | 24.75 Cr | 21.27 Cr | — |
| Effect Of Exchange Rate Changes | -0.51 Cr | 0.16 Cr | 0.05 Cr | -0.18 Cr | — |
| Changes In Cash | -6.21 Cr | -0.52 Cr | -11.64 Cr | 3.66 Cr | — |
| Financing Cash Flow | -51.72 Cr | -26.09 Cr | 41.76 Cr | 111.54 Cr | — |
| Interest Paid Cff | -13.13 Cr | -14.94 Cr | -12.59 Cr | -2.54 Cr | — |
| Cash Dividends Paid | -5.17 Cr | -6.85 Cr | -8.51 Cr | -8.51 Cr | — |
| Net Issuance Payments Of Debt | -33.12 Cr | -30.00 Cr | 38.92 Cr | 116.87 Cr | — |
| Net Short Term Debt Issuance | -1.77 Cr | -27.51 Cr | 24.01 Cr | 31.57 Cr | — |
| Short Term Debt Payments | -1.77 Cr | -27.51 Cr | — | — | — |
| Net Long Term Debt Issuance | -31.34 Cr | -2.49 Cr | 14.91 Cr | 85.30 Cr | — |
| Long Term Debt Payments | -31.34 Cr | -22.97 Cr | -17.14 Cr | -18.04 Cr | — |
| Long Term Debt Issuance | 0.00 | 20.47 Cr | 32.04 Cr | 103.35 Cr | — |
| Investing Cash Flow | -19.00 Cr | -22.61 Cr | -77.00 Cr | -116.59 Cr | — |
| Net Other Investing Changes | 0.49 Cr | -0.16 Cr | — | — | 10000.00 |
| Interest Received Cfi | 0.83 Cr | 1.89 Cr | 0.51 Cr | 0.26 Cr | — |
| Net Investment Purchase And Sale | 0.49 Cr | -0.16 Cr | 0.23 Cr | -0.51 Cr | — |
| Net PPE Purchase And Sale | 0.27 Cr | 0.06 Cr | 0.03 Cr | 0.18 Cr | — |
| Sale Of PPE | 0.27 Cr | 0.06 Cr | 0.03 Cr | 0.18 Cr | — |
| Capital Expenditure Reported | -20.59 Cr | -24.40 Cr | -77.76 Cr | -95.71 Cr | — |
| Operating Cash Flow | 64.51 Cr | 48.18 Cr | 23.60 Cr | 8.71 Cr | — |
| Taxes Refund Paid | -11.47 Cr | -11.67 Cr | -8.11 Cr | -17.11 Cr | — |
| Change In Working Capital | 9.95 Cr | 3.67 Cr | -20.84 Cr | -38.78 Cr | — |
| Change In Other Current Liabilities | -1.99 Cr | -6.44 Cr | 8.44 Cr | 2.86 Cr | — |
| Change In Other Current Assets | 1.42 Cr | 3.30 Cr | -7.82 Cr | -9.94 Cr | — |
| Change In Payable | 3.65 Cr | -3.73 Cr | 11.96 Cr | -10.07 Cr | — |
| Change In Inventory | 5.20 Cr | 9.23 Cr | -9.43 Cr | -13.16 Cr | — |
| Change In Receivables | 1.72 Cr | 0.53 Cr | -24.88 Cr | -9.16 Cr | — |
| Other Non Cash Items | 9.57 Cr | 11.09 Cr | -4.49 Cr | -7.70 Cr | — |
| Provisionand Write Offof Assets | 4.47 Cr | 0.69 Cr | 0.18 Cr | 0.47 Cr | — |
| Depreciation And Amortization | 16.80 Cr | 17.17 Cr | 20.70 Cr | 16.58 Cr | — |
| Amortization Cash Flow | 0.25 Cr | — | — | — | — |
| Depreciation | 16.55 Cr | 17.17 Cr | 20.70 Cr | 16.58 Cr | — |
| Net Foreign Currency Exchange Gain Loss | -0.77 Cr | -0.12 Cr | 0.08 Cr | 0.25 Cr | — |
| Gain Loss On Sale Of PPE | 0.49 Cr | -0.03 Cr | -0.02 Cr | -0.07 Cr | — |
| Net Income From Continuing Operations | 39.57 Cr | 31.95 Cr | 40.15 Cr | 53.50 Cr | — |
| Net Other Financing Charges | — | 26.00 Cr | 24.00 Cr | 5.79 Cr | 14.32 Cr |
| Net Business Purchase And Sale | — | — | 0.00 | -20.82 Cr | 0.00 |
| Purchase Of Business | — | — | 0.00 | -20.82 Cr | 0.00 |
| Issuance Of Capital Stock | — | — | — | — | 1.96 Cr |
| Net Common Stock Issuance | — | — | — | — | 1.96 Cr |
| Common Stock Issuance | — | — | — | — | 1.96 Cr |
| Sale Of Investment | — | — | — | — | 1.07 Cr |
| Gain Loss On Sale Of Business | — | — | — | — | 0.00 |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Hester Biosciences Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.